April is Sjögren’s Awareness Month. Kiniksa is proud to support the Sjögren’s Foundation through our corporate membership and to have hosted Dr. Lane Destro at our recent company town hall meeting, as we recognize the many people affected by this disease.
Kiniksa Pharmaceuticals
Biotechnology Research
Lexington, Massachusetts 18,706 followers
Relentless. Passionate. Focused
About us
Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. We have an experienced team that has advanced multiple product candidates in parallel that focus on a range of debilitating diseases with significant unmet medical need. We continue to explore expanding our pipeline in order to develop life-changing medicines for patients who need it most. We are focused on hiring and retaining a highly skilled team that has extensive experience and specific skill sets relating to the selection, development, and commercialization of transformative therapies. Whether in development, research, manufacturing, technical operations, or general / administrative functions, we depend on a brilliant team to support our mission of building a global, generational company. Our benefits are competitive, and we offer dynamic career opportunities across our organization fostering a culture that embraces passion and rapid execution.
- Website
-
http://www.kiniksa.com
External link for Kiniksa Pharmaceuticals
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Lexington, Massachusetts
- Type
- Public Company
- Founded
- 2015
Locations
-
Primary
Get directions
100 Hayden Ave
Lexington, Massachusetts 02421, US
-
Get directions
9191 Towne Centre Dr
Suite 330
San Diego, California 92122, US
-
Get directions
Clarendon House
2 Church Street
Hamilton, HM 11, BM
Employees at Kiniksa Pharmaceuticals
Updates
-
For patients with recurrent pericarditis (RP), their struggle can last for years. They suffer not only during flares, but in between flares as well. Join us at Booth 3719 at #ACC24 or visit our virtual booth at https://bit.ly/3VwJStj to learn more about the impact of RP and how it may be treated.
-
-
In a Harris Poll, the number 1 goal of treatment among patients with recurrent pericarditis (RP) was prevention of future flares. Join us at Booth 3719 at #ACC24 or visit our virtual booth at https://bit.ly/3VwJStj to learn more about the impact of RP and how it may be treated.
-
-
Join us at #ACC24 on April 7th for a panel discussion and Q&A about a long-term treatment strategy for recurrent pericarditis.
-
-
Join us at #ACC24 on April 7th for a panel discussion and Q&A about a long-term treatment strategy for recurrent pericarditis.
-
-
Patients with recurrent pericarditis (RP) often have a long journey with pain and inflammation to diagnosis. Join us at Booth 3719 at #ACC24 or visit our virtual booth at https://bit.ly/3VwJStj to learn more about identifying and treating RP.
-
-
Join us this weekend at #ACC24 as S. Allen Luis presents a poster of real-world evidence demonstrating increased adoption of a steroid-sparing treatment paradigm for recurrent pericarditis.
-
-
Planning on attending #ACC24 on April 6-8, 2024 in Atlanta? Visit Kiniksa Booth 3719 to learn about a treatment for recurrent pericarditis. If you can’t attend live, visit our virtual booth at https://bit.ly/3VwJStj.
-
-
Join us this weekend at #ACC24 as S. Allen Luis presents a poster of real-world evidence demonstrating increased adoption of a steroid-sparing treatment paradigm for recurrent pericarditis.
-